Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.

In multiple sclerosis (MS), treatment with the monoclonal antibody natalizumab effectively reduces the formation of acute lesions in the central nervous system (CNS). Natalizumab binds the integrin very late antigen (VLA)-4, expressed on the surface of immune cells, and inhibits VLA-4 dependent tran...

Full description

Bibliographic Details
Main Authors: Lars Börnsen, Jeppe Romme Christensen, Rikke Ratzer, Annette Bang Oturai, Per Soelberg Sørensen, Helle Bach Søndergaard, Finn Sellebjerg
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23226199/?tool=EBI